⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of OptymEdge and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
OptymEdge
↗Rockville, Maryland, USA
OptymEdge is a specialized, technology-enabled provider of visual function certification, training, and clinical trial support services, operating as a key division within the Emmes Group. The company is a leader in ophthalmic clinical research, offering the industry's first dedicated technology platform for ophthalmology trials, known as the Acuvera Suite, which integrates AI-powered imaging, data capture, and endpoint management.
Formed through the acquisition of Clinical Edge by Emmes, OptymEdge leverages over 30 years of experience to standardize visual function endpoints across global clinical trials. It serves a wide range of pharmaceutical and biotech sponsors, providing critical infrastructure for Phase I through Phase IV studies, including site certification, examiner training, and advanced reading center services.
CLASSIFICATION
SIZE & FINANCIALS
Employees:11-50
Revenue:$25M-$50M
Founded:2022
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, Gene therapy, Cell therapy
Active Trials:120
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Emmes Group
Acquired By:Emmes Group (2022-09-01)
Key Partnerships:RetinAI (AI integration for imaging), Streetlab (VR for functional vision assessments), National Eye Institute (NEI) (Long-standing research partner)
COMPETITION
Position:Leader
Competitors:Ora, Precision Vision, KliniTrial, Merit
LEADERSHIP
Key Executives:
Saqib Parkar - Managing Director
Amy Del Medico - Senior Director, Project Delivery & Transformation
LINKS
Website:optymedge.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with OptymEdge. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.